Love Charles Steele 4
4 · ENDOLOGIX INC /DE/ · Filed Oct 2, 2012
Insider Transaction Report
Form 4
Love Charles Steele
VP-Clinical Affairs
Transactions
- Award
Common Stock
2012-10-01$13.60/sh+36,765$500,004→ 36,765 total
Footnotes (5)
- [F1]25% vesting to occur upon the achievement of Nellix device revenue target for a month.
- [F2]25% vesting to occur upon U.S. regulatory approval of Nellix device.
- [F3]25% vesting to occur upon U.S. regulatory approval of Ventana device.
- [F4]25% vesting to occur upon U.S.regulatory approval of a second-generation AFX device.
- [F5]100% cliff vesting to occur 9/9/2016 in the event milestones are not achieved.